Drug Trial Radar · NCT07616700
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
73
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Dec 5, 2026
Study completion Dec 26, 2026
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, multicenter, open-label study. Eligible subjects who have completed the HSK39297-202 study will be enrolled.Starting dose is 200 mg QD.Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains \>1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.After the treatment period, subjects will enter the 4-week safety follow-up period.
Conditions
- IgA Nephropathy (IgAN)
Interventions
HSK39297 200mgQDDrug
Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains \>1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.
HSK39297 300mgQDDrug
Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains \>1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs) during treatment.Time frame: 48 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Completed
Peking University First Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.